Trade Virios Therapeutics, Inc. - VIRI CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
| Spread | 0.05 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
| Prev. Close* | 0.4 |
| Open* | 0.42 |
| 1-Year Change* | -33.33% |
| Day's Range* | 0.39 - 0.42 |
| 52 wk Range | 0.27-2.42 |
| Average Volume (10 days) | 234.46K |
| Average Volume (3 months) | 8.76M |
| Market Cap | 15.99M |
| P/E Ratio | -100.00K |
| Shares Outstanding | 19.26M |
| Revenue | N/A |
| EPS | -0.41 |
| Dividend (Yield %) | N/A |
| Beta | -100.00K |
| Next Earnings Date | Mar 18, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 22, 2024 | 0.40 | -0.02 | -4.76% | 0.42 | 0.42 | 0.40 |
| Apr 19, 2024 | 0.42 | 0.00 | 0.00% | 0.42 | 0.42 | 0.41 |
| Apr 18, 2024 | 0.42 | 0.00 | 0.00% | 0.42 | 0.42 | 0.41 |
| Apr 17, 2024 | 0.43 | -0.01 | -2.27% | 0.44 | 0.45 | 0.42 |
| Apr 16, 2024 | 0.43 | -0.03 | -6.52% | 0.46 | 0.46 | 0.42 |
| Apr 15, 2024 | 0.45 | -0.02 | -4.26% | 0.47 | 0.48 | 0.45 |
| Apr 12, 2024 | 0.48 | 0.03 | 6.67% | 0.45 | 0.50 | 0.45 |
| Apr 11, 2024 | 0.45 | 0.01 | 2.27% | 0.44 | 0.45 | 0.44 |
| Apr 10, 2024 | 0.43 | -0.01 | -2.27% | 0.44 | 0.44 | 0.42 |
| Apr 9, 2024 | 0.44 | 0.00 | 0.00% | 0.44 | 0.49 | 0.43 |
| Apr 8, 2024 | 0.42 | -0.01 | -2.33% | 0.43 | 0.47 | 0.41 |
| Apr 5, 2024 | 0.43 | -0.03 | -6.52% | 0.46 | 0.46 | 0.42 |
| Apr 4, 2024 | 0.46 | -0.01 | -2.13% | 0.47 | 0.49 | 0.46 |
| Apr 3, 2024 | 0.47 | -0.05 | -9.62% | 0.52 | 0.52 | 0.47 |
| Apr 2, 2024 | 0.50 | -0.04 | -7.41% | 0.54 | 0.54 | 0.48 |
| Apr 1, 2024 | 0.54 | 0.08 | 17.39% | 0.46 | 0.55 | 0.46 |
| Mar 28, 2024 | 0.45 | 0.00 | 0.00% | 0.45 | 0.51 | 0.42 |
| Mar 27, 2024 | 0.45 | 0.01 | 2.27% | 0.44 | 0.49 | 0.41 |
| Mar 26, 2024 | 0.41 | -0.05 | -10.87% | 0.46 | 0.50 | 0.41 |
| Mar 25, 2024 | 0.43 | -0.01 | -2.27% | 0.44 | 0.55 | 0.43 |
Virios Therapeutics, Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| No events scheduled | ||
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 |
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Total Operating Expense | 12.3153 | 15.6409 | 10.0054 | 2.1785 | 1.9615 |
| Selling/General/Admin. Expenses, Total | 4.24568 | 4.84525 | 9.81138 | 1.34232 | 1.10739 |
| Research & Development | 8.06963 | 10.7957 | 0.19401 | 0.83618 | 0.85411 |
| Operating Income | -12.3153 | -15.6409 | -10.0054 | -2.1785 | -1.9615 |
| Interest Income (Expense), Net Non-Operating | 0.06748 | -0.31933 | -0.38422 | -0.29513 | -0.1521 |
| Other, Net | 0.04322 | 0 | 0.00001 | ||
| Net Income Before Taxes | -12.2478 | -15.9603 | -10.3464 | -2.47363 | -2.11359 |
| Net Income After Taxes | -12.2478 | -15.9603 | -10.3464 | -2.47363 | -2.11359 |
| Net Income Before Extra. Items | -12.2478 | -15.9603 | -10.3464 | -2.47363 | -2.11359 |
| Net Income | -12.2478 | -15.9603 | -10.3464 | -2.47363 | -2.11359 |
| Income Available to Common Excl. Extra. Items | -12.2478 | -15.9603 | -10.3464 | -2.47363 | -2.11359 |
| Income Available to Common Incl. Extra. Items | -12.2478 | -15.9603 | -10.3464 | -2.47363 | -2.11359 |
| Diluted Net Income | -12.2478 | -15.9603 | -10.3464 | -2.47363 | -2.11359 |
| Diluted Weighted Average Shares | 11.0701 | 8.32931 | 8.30508 | 7.83249 | 7.83249 |
| Diluted EPS Excluding Extraordinary Items | -1.10639 | -1.91616 | -1.24579 | -0.31582 | -0.26985 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | |||
| Diluted Normalized EPS | -1.10639 | -1.91616 | -1.24579 | -0.31582 | -0.26985 |
| Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 |
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Total Operating Expense | 1.47722 | 1.55729 | 2.08972 | 2.59232 | 3.67206 |
| Selling/General/Admin. Expenses, Total | 0.91937 | 1.05957 | 0.818 | 0.96995 | 1.26562 |
| Research & Development | 0.55784 | 0.49771 | 1.27171 | 1.62237 | 2.40644 |
| Operating Income | -1.47722 | -1.55729 | -2.08972 | -2.59232 | -3.67206 |
| Interest Income (Expense), Net Non-Operating | 0.03631 | 0.04042 | 0.04516 | 0.01661 | 0.0048 |
| Net Income Before Taxes | -1.4409 | -1.51686 | -2.04456 | -2.57572 | -3.66726 |
| Net Income After Taxes | -1.4409 | -1.51686 | -2.04456 | -2.57572 | -3.66726 |
| Net Income Before Extra. Items | -1.4409 | -1.51686 | -2.04456 | -2.57572 | -3.66726 |
| Net Income | -1.4409 | -1.51686 | -2.04456 | -2.57572 | -3.66726 |
| Income Available to Common Excl. Extra. Items | -1.4409 | -1.51686 | -2.04456 | -2.57572 | -3.66726 |
| Income Available to Common Incl. Extra. Items | -1.4409 | -1.51686 | -2.04456 | -2.57572 | -3.66726 |
| Diluted Net Income | -1.4409 | -1.51686 | -2.04456 | -2.57572 | -3.66726 |
| Diluted Weighted Average Shares | 18.4114 | 18.3304 | 11.0701 | 18.3304 | 8.33039 |
| Diluted EPS Excluding Extraordinary Items | -0.07826 | -0.08275 | -0.18469 | -0.14052 | -0.44023 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -0.07826 | -0.08275 | -0.18469 | -0.14052 | -0.44023 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Current Assets | 8.36976 | 15.7767 | 31.4727 | 0.3159 | 0.0424 |
| Cash and Short Term Investments | 7.03099 | 14.0082 | 29.7954 | 0.30938 | 0.03003 |
| Cash | 7.03099 | 14.0082 | 29.7954 | 0.30938 | 0.03003 |
| Prepaid Expenses | 1.33876 | 1.7685 | 1.67737 | 0.00652 | 0.01237 |
| Total Assets | 8.36976 | 15.7767 | 31.4727 | 0.3159 | 0.06594 |
| Other Long Term Assets, Total | 0 | 0.02354 | |||
| Total Current Liabilities | 1.04326 | 1.27562 | 1.53184 | 1.62087 | 1.32633 |
| Accounts Payable | 0.57316 | 0.35386 | 0.36891 | 0.03542 | 0.14566 |
| Accrued Expenses | 0.4701 | 0.92176 | 1.16294 | 1.58545 | 1.18068 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 1.04326 | 1.27562 | 1.53184 | 5.25841 | 1.32633 |
| Total Long Term Debt | 0 | 0 | 0 | 3.63754 | 0 |
| Long Term Debt | 0 | 3.63754 | 0 | ||
| Total Equity | 7.32649 | 14.5011 | 29.9409 | -4.94251 | -1.2604 |
| Preferred Stock - Non Redeemable, Net | 0 | 0.075 | 1.28348 | ||
| Common Stock | 0.00183 | 0.00083 | 0.00083 | 12.6012 | 12.6012 |
| Retained Earnings (Accumulated Deficit) | -56.1732 | -43.9254 | -27.9651 | -17.6187 | -15.1451 |
| Total Liabilities & Shareholders’ Equity | 8.36976 | 15.7767 | 31.4727 | 0.3159 | 0.06594 |
| Total Common Shares Outstanding | 18.3304 | 8.33039 | 8.30508 | 7.83249 | 7.83249 |
| Additional Paid-In Capital | 63.4979 | 58.4256 | 57.9052 |
| Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 5.21212 | 6.52062 | 8.36976 | 10.858 | 9.0401 |
| Cash and Short Term Investments | 4.59013 | 5.33254 | 7.03099 | 9.7884 | 7.69504 |
| Cash | 4.59013 | 5.33254 | 7.03099 | 9.7884 | 7.69504 |
| Prepaid Expenses | 0.62199 | 1.18808 | 1.33876 | 1.06958 | 1.34506 |
| Total Assets | 5.21212 | 6.52062 | 8.36976 | 10.858 | 9.0401 |
| Total Current Liabilities | 0.52003 | 0.54929 | 1.04326 | 1.63314 | 1.89773 |
| Accounts Payable | 0.21431 | 0.13509 | 0.57316 | 0.67942 | 0.66554 |
| Accrued Expenses | 0.30573 | 0.4142 | 0.4701 | 0.95373 | 1.23219 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 0.52003 | 0.54929 | 1.04326 | 1.63314 | 1.89773 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 4.69209 | 5.97133 | 7.32649 | 9.22484 | 7.14236 |
| Preferred Stock - Non Redeemable, Net | |||||
| Common Stock | 0.00186 | 0.00183 | 0.00183 | 0.00183 | 0.00083 |
| Additional Paid-In Capital | 64.1134 | 63.6596 | 63.4979 | 63.3517 | 58.6945 |
| Retained Earnings (Accumulated Deficit) | -59.131 | -57.6901 | -56.1732 | -54.1287 | -51.5529 |
| Total Liabilities & Shareholders’ Equity | 5.21212 | 6.52062 | 8.36976 | 10.858 | 9.0401 |
| Total Common Shares Outstanding | 18.6085 | 18.3304 | 18.3304 | 18.3304 | 8.33039 |
| Treasury Stock - Common | -0.29224 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -12.2478 | -15.9603 | -10.3464 | -2.47363 | -2.11359 |
| Cash From Operating Activities | -11.4678 | -15.6896 | -3.8952 | -2.09215 | -1.19596 |
| Non-Cash Items | 0.58266 | 0.32288 | 7.42526 | 0.065 | 0.04851 |
| Changes in Working Capital | 0.19738 | -0.05219 | -0.97406 | 0.31648 | 0.86913 |
| Cash From Financing Activities | 4.49061 | -0.0976 | 33.3812 | 2.37151 | 1.15047 |
| Financing Cash Flow Items | 4.49061 | -0.29517 | -0.13826 | -0.05849 | 1.15047 |
| Issuance (Retirement) of Debt, Net | 0 | 1.99413 | 2.43 | 0 | |
| Net Change in Cash | -6.97719 | -15.7872 | 29.486 | 0.27936 | -0.04549 |
| Cash Interest Paid | 0 | 0.01255 | |||
| Issuance (Retirement) of Stock, Net | 0 | 0.19756 | 31.5253 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -1.51686 | -12.2478 | -10.2033 | -7.62756 | -3.96031 |
| Cash From Operating Activities | -1.69845 | -11.4678 | -8.79639 | -6.31314 | -2.65602 |
| Non-Cash Items | 0.1617 | 0.58266 | 0.43313 | 0.26886 | 0.13191 |
| Changes in Working Capital | -0.34328 | 0.19738 | 0.97376 | 1.04556 | 1.17239 |
| Cash From Financing Activities | 0 | 4.49061 | 4.5766 | 0 | 0 |
| Financing Cash Flow Items | 0 | 4.49061 | 4.5766 | 0 | 0 |
| Issuance (Retirement) of Stock, Net | 0 | 0 | 0 | 0 | |
| Issuance (Retirement) of Debt, Net | |||||
| Net Change in Cash | -1.69845 | -6.97719 | -4.21979 | -6.31314 | -2.65602 |
| Cash Interest Paid |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Virios Therapeutics, Inc. Company profile
About Virios Therapeutics Inc
Virios Therapeutics, Inc., formerly Virios Therapeutics, LLC., is a development-stage biotechnology company focused on advancing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia (FM). Its lead development candidate is IMC-1, which is a fixed dose combination of famciclovir and celecoxib. IMC-1 represents a combination antiviral therapy designed to synergistically suppress Herpes Simplex Virus-1 (HSV-1) activation and replication. Its HSV-1 root cause of chronic illnesses such as FM, irritable bowel disease (IBS), chronic fatigue syndrome and functional somatic syndrome. The Company is developing its initial candidate, IMC-1, for people who are suffering from fibromyalgia.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Virios Therapeutics Inc revenues was not reported. Net loss increased 54% to $16M. Higher net loss reflects Research and development increase from $194K to $10.8M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$1.25 to -$1.92.
| Industry: | Bio Therapeutic Drugs |
44 Milton Avenue
ALPHARETTA
GEORGIA 30009
US
Income Statement
- Annual
- Quarterly
News
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024
US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024
US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024
Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024
US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024
How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com